Company Description
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection.
The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment.
It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers.
The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Country | Belgium |
| Founded | 2003 |
| IPO Date | Nov 4, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Michael McGarrity |
Contact Details
Address: CAP Business Center, Rue d’Abhooz 31 Herstal, 4040 Belgium | |
| Phone | 32 4 257 70 21 |
| Website | mdxhealth.com |
Stock Details
| Ticker Symbol | MDXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.46 |
| CIK Code | 0001872529 |
| CUSIP Number | 58286E102 |
| ISIN Number | US58286E1029 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Michael K. McGarrity | Chief Executive Officer and Executive Director |
| Ron Kalfus CPA | Chief Financial Officer |
| Joseph Sollee J.D., LLM | Executive Vice President of Corporate Development and General Counsel |
| John A. Bellano | Chief Commercial Officer |
| Miriam Reyes | Executive Vice President of Operations |
| Dr. Jason Poole Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Oct 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 3, 2024 | SCHEDULE 13G/A | Filing |
| Sep 30, 2024 | 6-K | Report of foreign issuer |
| Sep 26, 2024 | 424B5 | Filing |
| Sep 25, 2024 | 424B5 | Filing |